Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET
August 25 2020 - 4:01PM
Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology
company focused on liver-directed treatment of rare primary and
metastatic cancers, today announced management will present at the
LD Micro 500 Virtual Conference Tuesday, September 01, 2020 3:00 PM
ET.
A live webcast of the presentation will be available to the
public at https://www.webcaster4.com/Webcast/Page/2019/36399. The
webcast will be archived for 90 days following the live
presentation.
Management will be available for one-on-one meetings, to
schedule a meeting with management, please contact the conference
James@HaydenIR.com.
About LD Micro LD Micro began in 2006 with the
sole purpose of being an independent resource in the microcap
space. What started as a newsletter highlighting unique companies
has transformed into an event platform hosting several influential
conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to provide intraday information on the entire sector exclusively.
LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
For those interested in attending, please contact David Scher
at david@ldmicro.com or
visit www.ldmicro.com for more
information.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
Our investigational product Melphalan Hydrochloride for Injection
for use with the Delcath Hepatic Delivery System (Melphalan/HDS) –
is designed to administer high-dose chemotherapy to the liver while
minimizing systemic exposure and associated side effects. In
addition to the Phase 3 FOCUS Trial, we have initiated a global
Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC)
called The ALIGN Trial. We currently are also evaluating other
forms of metastatic liver cancers. Melphalan/HDS has not been
approved by the U.S. Food & Drug Administration (FDA) for sale
in the U.S. In Europe, our system is marketed under the trade name
Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT)
and has been CE Marked and used at major medical centers to treat a
wide range of cancers of the liver. CHEMOSAT is being marketed
under an exclusive licensing agreement with medac GmbH, a privately
held multi-national pharmaceutical company headquartered in Germany
that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases.
Contact:
Hayden IR James Carbonara (646)-755-7412 james@haydenir.com
Brett Maas (646) 536-7331 brett@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Sep 2023 to Sep 2024